Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to alpha2u-globulin.

@article{Leavens2009PhysiologicallyBP,
  title={Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to alpha2u-globulin.},
  author={T. Leavens and S. Borghoff},
  journal={Toxicological sciences : an official journal of the Society of Toxicology},
  year={2009},
  volume={109 2},
  pages={
          321-35
        }
}
  • T. Leavens, S. Borghoff
  • Published 2009
  • Chemistry, Medicine
  • Toxicological sciences : an official journal of the Society of Toxicology
Current physiologically based pharmacokinetic (PBPK) models for the fuel additive methyl tertiary butyl ether (MTBE) and its metabolite tertiary butyl alcohol (TBA) have not included a mechanism for chemical binding to the male rat-specific protein alpha2u-globulin, which has been postulated to be responsible for renal effects in male rats observed in toxicity and carcinogenicity studies with MTBE. The objective of this work was to expand the previously published models for MTBE to include… Expand
Physiologically based pharmacokinetic model for ethyl tertiary‐butyl ether and tertiary‐butyl alcohol in rats: Contribution of binding to α2u–globulin in male rats and high‐exposure nonlinear kinetics to toxicity and cancer outcomes
TLDR
A physiologically based pharmacokinetic model was developed based on a previously published model for methyl tertiary‐butyl ether, supporting a male‐rat‐specific mode of action for TBA‐induced kidney tumors and predicted nonlinear kinetics at ETBE inhalation exposure concentrations above ~2000 ppm, based on blood AUC0–∞ for ETBE and TBA. Expand
Physiologically based pharmacokinetic rat model for methyl tertiary-butyl ether; comparison of selected dose metrics following various MTBE exposure scenarios used for toxicity and carcinogenicity evaluation.
TLDR
This model can now be used to evaluate route-to-route extrapolation issues concerning MTBE exposures but also as a means of comparing potential dose metrics that may provide insight to differences in biological responses observed in rats following different routes of MTBE exposure. Expand
A physiologically based pharmacokinetic model for the prediction of the depletion of methyl-3-quinoxaline-2-carboxylic acid, the marker residue of olaquindox, in the edible tissues of pigs.
TLDR
A physiologically based pharmacokinetic model for methyl-3-quinoxaline-2-carboxylic acid, the marker residue of OLA, was developed in pigs based on the assumptions of the flow-limited distribution, hepatic metabolism, and renal excretion and proved the good applicability of the model in food safety risk assessment. Expand
Development and application of a rat PBPK model to elucidate kidney and liver effects induced by ETBE and tert-butanol.
TLDR
The hypothesis that TBA mediates the noncancer kidney and liver effects following ETBE administration is supported; however, additional factors besides internal dose are necessary to explain the induction of liver and kidney tumors. Expand
A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse.
TLDR
A physiologically based pharmacokinetic (PBPK) model for ATR and its main chlorotriazine metabolites (Cl-TRIs) desethyl atrazine (DE), desisopropyl atazine (DIP), and didealkyl atrazines (DACT) was developed for the adult male C57BL/6 mouse, and provides insights into tissue dosimetry for rats. Expand
Human health screening level risk assessments of tertiary-butyl acetate (TBAC): Calculated acute and chronic reference concentration (RfC) and Hazard Quotient (HQ) values based on toxicity and exposure scenario evaluations
TLDR
The screening level risk assessments confirm low human health concerns with most uses of TBAC and indicate that further data-informed refinements can address problematic health/exposure scenarios. Expand
A subchronic (180-day) oral toxicity study of ethyl tertiary-butyl ether, a bioethanol, in rats
TLDR
The no observed adverse effect level of ETBE was 100 mg/kg b.w./day under the conditions tested, suggesting enhanced metabolic activity in rats. Expand
A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results.
TLDR
It is advocated that this PBTK model, called IndusChemFate, is suitable for 'first tier assessments' and for early explorations of the fate of chemicals and/or metabolites in the human body and should be applied as a generic model applicable to multiple compounds. Expand
A one-generation reproductive toxicity study of ethyl tertiary butyl ether in rats.
TLDR
The results lead to the conclusion that the no-observed-adverse-effect-level (NOAEL) of ETBE on both parental rats and their offspring is 300 mg/kg-d under the current study condition. Expand
Reassessment of MTBE cancer potency considering modes of action for MTBE and its metabolites
TLDR
It was determined that MTBE most likely does not increase cancer risk unless chronic exposures induce target-tissue toxicity, including in sensitive individuals, and is among the weakest 10% of chemical carcinogens evaluated by EPA. Expand
...
1
2
...

References

SHOWING 1-10 OF 69 REFERENCES
Development of physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fisher-344 rats.
TLDR
A physiologically based pharmacokinetic model for MTBE and TBA in rats will form the basis for a human model and a better assessment of the potential toxic and cancer risk for humans exposed to MTBE can be made. Expand
A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses.
TLDR
By incorporating an understanding of the metabolic processes, this PBPK model can be used to predict blood levels of MTBE, which is important in determining target tissue dose estimates for risk assessment. Expand
Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether.
TLDR
This PBPK model represents the most comprehensive and accurate description of MTBE and TBA pharmacokinetics in humans to date and can be generalized to other environmental chemicals under this framework given appropriate empirical measurement data. Expand
In vitro uptake of methyl tert-butyl ether in male rat kidney: use of a two-compartment model to describe protein interactions.
TLDR
A technique useful in estimating the dissociation constant for a volatile chemical and a protein, as well as explain the process that contributes to the uptake of MTBE into male rat kidney homogenate in vitro are illustrated. Expand
Evaluation of the in vivo interaction of methyl tert-butyl ether with alpha2u-globulin in male F-344 rats.
TLDR
Findings provide indirect evidence that MTBE interacts with a male-specific protein such as alpha2u in male F-344 rats, and supports the alpha2U mechanism as a cause of MTBE-induced protein droplet nephropathy in male rats. Expand
A physiological model for ligand-induced accumulation of alpha 2u globulin in male rat kidney: roles of protein synthesis and lysosomal degradation in the renal dosimetry of 2,4,4-trimethyl-2-pentanol.
TLDR
This model reproduces time course data of blood and kidney TMP-2-OH and renal alpha2u concentrations, suggesting that renal accumulation ofalpha2u is not simply a consequence of reduced proteolytic degradation but may also involve a transient increase in hepatic alpha2U production. Expand
Evaluation of thein VivoInteraction of Methyltert-Butyl Ether with α2u-Globulin in Male F-344 Rats☆
Methyl tert-butyl ether (MTBE), a fuel additive blended into unleaded gasoline, decreases emissions of selected air pollutants. Exposure to MTBE causes a low incidence of renal tumors in male, butExpand
Metabolism of methyl tert-butyl ether and other gasoline ethers by human liver microsomes and heterologously expressed human cytochromes P450: identification of CYP2A6 as a major catalyst.
TLDR
It is demonstrated that human liver is also active in the oxidative metabolism of ETBE and TAME, and that in human liver, CYP2A6 is the major enzyme responsible for the metabolism of MTBE, ETBE, and Tame. Expand
Development and Use of PBPK Modeling and the Impact of Metabolism on Variability in Dose Metrics for the Risk Assessment of Methyl Tertiary Butyl Ether (MTBE)
MTBE is a volatile organic compound (VOC) that is used as an oxygenate additive to gasoline. This chemical has been detected in groundwater and in surface water reservoirs due to leaks andExpand
2,2,4-Trimethylpentane-induced nephrotoxicity. II. The reversible binding of a TMP metabolite to a renal protein fraction containing alpha 2u-globulin.
TLDR
These studies provide the first evidence for a reversible binding between a metabolite of TMP and a male-rat-specific protein in the kidney and thus provide important insight delineating a potential mechanism of hydrocarbon-induced hyaline-droplet nephropathy. Expand
...
1
2
3
4
5
...